PDE4A and atopic eczema: PDE4 inhibitors have been found to reduce the level of inflammatory response for the treatment of inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis and other diseases, such as Apt can be used for psoriatic arthritis, and rofluskast can be used to treat asthma.